Sign In
Buy SNDX
$18.34
-0.0500 (-0.272%)
At Close: Jun 03, 2026
Syndax Announces Participation in June Investor Conferences
07:00am, Thursday, 29'th May 2025
NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Me
Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr)
09:30am, Wednesday, 14'th May 2025
– Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and NUP98r –
Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer
04:01pm, Monday, 12'th May 2025
- Dr. Nicholas Botwood comes to Syndax from BMS and brings 25 years of industry experience leading drug development, R&D strategy and global commercialization of novel oncology therapeutics -
Wall Street Analysts See a 219.98% Upside in Syndax (SNDX): Can the Stock Really Move This High?
11:00am, Friday, 09'th May 2025
The consensus price target hints at a 220% upside potential for Syndax (SNDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate re
Syndax Announces Participation in May Investor Conferences
07:00am, Thursday, 08'th May 2025
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Me
Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood
04:01pm, Wednesday, 07'th May 2025
– Primary endpoint met in R/R mNPM1 AML patients in pivotal Phase 2 portion of the AUGMENT-101 trial – – Robust remission rates in heavily pre-treated R/R mNPM1 AML population with nearly 50% ov
Syndax Pharmaceuticals, Inc. (SNDX) Q1 2025 Earnings Call Transcript
11:18pm, Monday, 05'th May 2025
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q1 2025 Earnings Conference Call May 5, 2025 4:30 PM ET Company Participants Sharon Klahre - Head of IR Michael Metzger - Chief Executive Officer and Direct
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Tops Revenue Estimates
06:10pm, Monday, 05'th May 2025
Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $0.98 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to loss of $0.85 per share a year ago.
Syndax Reports First Quarter 2025 Financial Results and Provides Business Update
04:01pm, Monday, 05'th May 2025
– $20.0 million in Revuforj ® (revumenib) net revenue in first full quarter of launch –
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:05pm, Friday, 02'nd May 2025
NEW YORK, May 02, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on May 1, 20
Syndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025
07:00am, Monday, 28'th Apr 2025
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:05pm, Friday, 04'th Apr 2025
NEW YORK, April 04, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced
Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum
07:00am, Wednesday, 02'nd Apr 2025
NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:05pm, Wednesday, 05'th Mar 2025
NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced
Syndax Pharmaceuticals, Inc. (SNDX) Q4 2024 Earnings Call Transcript
11:46am, Monday, 03'rd Mar 2025
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q4 2024 Earnings Conference Call March 3, 2025 8:00 AM ET Company Participants Sharon Klahre - Head of IR Michael Metzger - CEO Steve Closter - CCO Neil Gal
